Loading clinical trials...
Loading clinical trials...
Real-World Data on the Treatment of Lung Cancer Patients With the Immune-Checkpoint Inhibitor Tislelizumab - the ReWoLuTe Study
Conditions
Locations
2
Austria
Universitätsklinikum St. Pölten - Lilienfeld, Karl Landsteiner Privatuniversität für Gesundheitswissenschaften
Sankt Pölten, Lower Austria, Austria
Krankenhaus Nordwest
Frankfurt am Main, Hesse, Germany
Start Date
December 23, 2025
Primary Completion Date
December 23, 2032
Completion Date
January 23, 2033
Last Updated
April 3, 2026
NCT07361497
NCT06305754
NCT05920356
NCT07239063
NCT06128551
NCT07393490
Lead Sponsor
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions